marion dorsch profiles  facebook facebookemail or phonepasswordforgot accountenglish usespañolfrançais franceالعربيةportuguês brasilitaliano한국어deutschहिन्दीmessengerfacebook litepeopleplacesgameslocationscelebritiesmarketplacegroupsrecipesmomentsinstagramaboutcreate adcreate pagedeveloperscareersprivacycookiesad choicestermssettingsactivity log facebook   marion dorschs involvement in venture capital via agios pharmaceuticals want to see morewant to find out who got funded and who’s funding the next big thing in real time all across the world tailored to your specific areas of focus deals per dayget access to the most exhaustive worldwide funding watch on the webcomprehensive funding informationknow about who invested in a company which sites covered the event the funding history etcexclusive insightsview original analytics such as most dynamic industries most active investors and morestay awareget emailed when deals critical to your business happen filter by region industry and topics of interestas seen onhave a loginsign inregister nowits freeuse your social accountor fill in the quick formregister nowpromise we wont spamsign invia your social accountvia your existing wgf accountremember meregister its freeforgot your passwordsign inforgot your passwordenter your email and we will send you your new passwordreset passwordthe worlds largest funding basepeoplemariondorschsectionpeoplesubsectiondetailid search deals by company name industry location investors search mariondorschget alertedif marion dorsch gets fundedmarion dorschagios pharmaceuticals  vp biologydeals involving marion dorsch raised with agios pharmaceuticals on december  raised with agios pharmaceuticals on april  raised with agios pharmaceuticals on november  raised with agios pharmaceuticals on april please note that all data is automatically extracted and errors can occurthe whogotfunded team has not necessarily reviewed the information in this page and has not determined if it is accurate and completesome of the profile information was collected using the crunchbase api for more details on the profile please check marion dorsch on crunchbaseinaccurate data help us improve whogotfunded post a comment marion dorsch addedit   you are here scientific experts  novartis institutes for biomedical research  dorsch  marion dorsch research topicsspodopteraantibody specificityprotein sequence analysisliquid chromatographyphosphorylationrecombinant proteinswestern blottingbinding sitesphthalazinesexperimental neoplasmsg protein coupled receptorsoral administrationprotein bindingfeedbackstructure activity relationshipkidneyrepressor proteinsnuclear proteinsmembrane proteinstumor cell linegenetic transcriptioninbred nod miceneoplastic gene expression regulationscid micemultiple myelomacell growth processesproto oncogene proteinsisoenzymesnf kappa bcd antigensgenomes and genesirak productsbmi productsprkcq productsnlrc productsripk productsirak productstlr productsripk productsspecieshumanmousemarion dorschsummaryaffiliation novartis institutes for biomedical researchpublications participation of rip in lipopolysaccharide signaling is independent of its kinase activitychafen lumillennium pharmaceuticals inc cambridge massachusetts  usaj biol chem   nucleotide binding to card and its role in cardmediated caspase activationchafen lumillennium pharmaceuticals inc  landsdowne street cambridge ma  usabiochem biophys res commun   validating cancer drug targetsjohn d bensonnovartis institutes for biomedical research  massachusetts avenue cambridge massachusetts  usanature   identification of a regulatory autophosphorylation site in the serinethreonine kinase ripmarion dorschmillennium pharmaceuticals inc  landsdowne st cambridge ma  usacell signal   regulation of irak kinase activity via autophosphorylation within its activation loophong chengdepartment of inflammation millennium pharmaceuticals inc cambridge ma  usabiochem biophys res commun  7 the polycomb group protein bmi is essential for the growth of multiple myeloma cellszainab jaganinovartis institutes for biomedical research cambridge massachusetts usacancer res   mice deficient in pkc theta demonstrate impaired in vivo t cell activation and protection from t cellmediated inflammatory diseaseskaren andersoninflammation department millennium pharmaceuticals inc  landsdowne st cambridge ma  usaautoimmunity   aminobenzylphthalazines as orally bioavailable smoothened antagonists with antitumor activitykaren millermoslindepartment of global discovery chemistry novartis institutes for biomedical research cambridge massachusetts  usaj med chem   targeted inhibition of mutant idh in leukemia cells induces cellular differentiationfang wangagios pharmaceuticals cambridge ma   usascience   interfering with resistance to smoothened antagonists by inhibition of the pik pathway in medulloblastomasilvia buonamicinovartis institutes for biomedical research cambridge ma  usasci transl med ra collaboratorskaren andersonzainab jaganimarkus warmuthfang wangandrew kernytskyhua yangwei liuchafen luping lihong chengyue chentao wanghong renshunqi yanjing yuanyi gaostefan peukertchristopher c frasersusan weecarlos garciaecheverriazhi lisauveur michel mairalin wangdulce solerrui zhanganthony j coyleallan brasierantonella casoladmitri wiederschainsilvia buonamicijoseph f kelleherjuliet williamsribo guoanthony vattaykaren millermoslinmedhi lahmarchristoph lengauerwilliam r sellershemalatha indukurijohn d bensonkathy hsiaojohn greend neil watkinskimberly j briggsyung mae yaoshifeng panxu wupaul fordjourmichael morrisseyjohn e monahanbeatriz ospinaqunyan yulance ostromdustin l andersonanlai wangrishi k jainadam amaralmiao daitao shengyingchuan sunyanhong liarun ramamurthymichael a mcewanaaron bourretfeng hemelissa matsumotonaeem yusuffwieslawa maniaralawrence perezhuangshu leiluis llamaswalter michaelrajesh karkievelyne lauretwilliam vainchenkersonia poiraultcyril catelainjean luc villevalolivier albaglisusan a cornellkennonsunkyu kimshawn m castroroberto p garofalosha mei liaomagdalena leszczynieckalee ann feeney detail informationpublications participation of rip in lipopolysaccharide signaling is independent of its kinase activitychafen lumillennium pharmaceuticals inc cambridge massachusetts  usaj biol chem  these results demonstrate that ripmediated lps signaling is independent of its kinase activity our findings strongly suggest that rip functions as an adaptor molecule in transducing signals from immune receptors nucleotide binding to card and its role in cardmediated caspase activationchafen lumillennium pharmaceuticals inc  landsdowne street cambridge ma  usabiochem biophys res commun  thus card function is dependent on the nucleotidebinding site our data provide insights into the molecular mechanisms of cardmediated caspase activation validating cancer drug targetsjohn d bensonnovartis institutes for biomedical research  massachusetts avenue cambridge massachusetts  usanature  although the outcome of validation studies can guide cancer research programmes strictly defined universal validation criteria have not been established identification of a regulatory autophosphorylation site in the serinethreonine kinase ripmarion dorschmillennium pharmaceuticals inc  landsdowne st cambridge ma  usacell signal  in summary our results indicate that s7 is a regulatory autophosphorylation site for rip and that s7 phosphorylation can be used to monitor the activation state of rip regulation of irak kinase activity via autophosphorylation within its activation loophong chengdepartment of inflammation millennium pharmaceuticals inc cambridge ma  usabiochem biophys res commun  7the present data indicate that the kinase activity of irak is dependent on the autophosphorylations at t t and s in the activation loop the polycomb group protein bmi is essential for the growth of multiple myeloma cellszainab jaganinovartis institutes for biomedical research cambridge massachusetts usacancer res  therefore these studies not only highlight bmi as a cancerdependent factor in multiple myeloma but also elucidate a novel antiapoptotic mechanism for bmi function involving the suppression of bim mice deficient in pkc theta demonstrate impaired in vivo t cell activation and protection from t cellmediated inflammatory diseaseskaren andersoninflammation department millennium pharmaceuticals inc  landsdowne st cambridge ma  usaautoimmunity  a fundamental role for pkc theta in t cell activation and in the development of t cellmediated inflammatory diseases is indicated by these results aminobenzylphthalazines as orally bioavailable smoothened antagonists with antitumor activitykaren millermoslindepartment of global discovery chemistry novartis institutes for biomedical research cambridge massachusetts  usaj med chem  this compound displayed a good pharmacokinetic profile and also afforded tumor regression in a genetic mouse model of medulloblastoma targeted inhibition of mutant idh in leukemia cells induces cellular differentiationfang wangagios pharmaceuticals cambridge ma   usascience  these data provide proofofconcept that inhibitors targeting mutant idhrq could have potential applications as a differentiation therapy for cancer interfering with resistance to smoothened antagonists by inhibition of the pik pathway in medulloblastomasilvia buonamicinovartis institutes for biomedical research cambridge ma  usasci transl med ra our findings may be useful in informing treatment strategies for medulloblastoma a small molecule inhibitor of mutant idh rescues cardiomyopathy in a dhydroxyglutaric aciduria type ii mouse modelfang wangagios pharmaceuticals inc  sidney street cambridge ma   usaj inherit metab dis 7 these findings demonstrate the potential therapeutic benefit of an idhrq inhibitor in patients with dhga type ii pik pathway activation mediates resistance to mek inhibitors in kras mutant cancerssusan weenovartis institutes for biomedical research cambridge ma usacancer res  our study provides molecular insights that help explain the heterogeneous response of kras mutant cancers to mek pathway inhibition and presents a strong rationale for the clinical testing of combination mek and pik targeted therapies hedgehog pathway activation in chronic myeloid leukemiazainab jaganidepartment of oncology novartis institutes for biomedical research cambridge ma usacell cycle   pkegvegf induces monocyte differentiation and activationmarion dorschmillennium pharmaceuticals inc  landsdowne st cambridge ma  usaj leukoc biol  pk induces a distinct monocytederived cell population which is primed for release of proinflammatory cytokines that favor a t helper cell type  response ikkepsilon regulates viralinduced interferon regulatory factor activation via a redoxsensitive pathwayhemalatha indukuridepartment of pediatrics university of texas medical branch galveston tx   usavirology   distinct effects of the soluble versus membranebound forms of the notch ligand delta on human cdcdlow cell expansion and differentiationmedhi lahmaru inserm institut gustave roussy university paris xi pr  villejuif francestem cells  altogether these results suggest that part of sold activity did not rely upon canonical notch pathway   labomeorg   all rights researvedprinceton new jersey  usalast updated february   blueprint medicines announces appointment of marion dorsch phd as chief scientific officer and the transition of christoph lengauer phd mba to a newly created executive vice president role  the business journals menu select a city national albany albuquerque atlanta austin baltimore birmingham boston buffalo charlotte chicago cincinnati columbus dallas dayton denver greensborowinstonsalem honolulu houston jacksonville kansas city los angeles louisville memphis miamifort lauderdale milwaukee minneapolisst paul nashville new york orlando philadelphia phoenix pittsburgh portland raleighdurham sacramento san antonio san francisco seattle silicon valley st louis tampa bay washington dc wichita limited time offer subscribe now search × close sign in sign in your account your account welcome your account sign in existing users create your free account dont have an account your account subscriptions newsletters custom notifications my custom site manage site users sign out sign in sign in your account search home industries  topics all industries  topics banking  financial services career  workplace commercial real estate education energy food  lifestyle government  regulations health care manufacturing media  marketing philanthropy  nonprofits professional services residential real estate retailing sports business technology transportation travel  tourism sponsored content cre now we value your business office environments small business marketing know your neighborhood news news latest news business pulse press releases lists  awards lists all lists build your own lists people  companies companies top private companies find businesses for sale search for company news people people on the move contact top executives executive profiles search for people in the news events events business event calendar nominations more… jobs find or post a job store subscriptions reprints  more how to grow your business advance your career thought leadership trends tips and insights from our partners subscribers manage your account about  contact about the business journals advertise help  faqs call center directory apps  syndication newsletters acbj publications bizwomen upstart hemmings sports business journal inside lacrosse bostinno dcinno chicagoinno austininno select a city national albany albuquerque atlanta austin baltimore birmingham boston buffalo charlotte chicago cincinnati columbus dallas dayton denver greensborowinstonsalem honolulu houston jacksonville kansas city los angeles louisville memphis miamifort lauderdale milwaukee minneapolisst paul nashville new york orlando philadelphia phoenix pittsburgh portland raleighdurham sacramento san antonio san francisco seattle silicon valley st louis tampa bay washington dc wichita follow us twitter linkedin facebook google  press releases blueprint medicines announces appointment of marion dorsch phd as chief scientific officer and the transition of christoph lengauer phd mba to a newly created executive vice president role  effective november    nov   pm est cambridge mass nov   prnewswire  blueprint medicines corporation nasdaq bpmc a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases today announced that marion dorsch phd will succeed christoph lengauer phd mba as chief scientific officer effective november   dr dorsch will join the executive management team and will be responsible for setting the scientific strategy and priorities for blueprint medicines as well as overseeing daytoday research operations dr lengauer will transition to the role of executive vice president where he will drive an integrated approach to progressing blueprint medicines portfolio of investigational drugs i am delighted to welcome marion to blueprint she is a seasoned leader with a deep understanding of human biology and a wealth of experience identifying novel drug targets for cancer and rare genetic diseases including significant experience in cancer immunology said jeff albers chief executive officer of blueprint medicines her expertise driving drug discovery across both internal and partnered programs will be invaluable as we continue to explore the vast potential of kinase therapies i am thrilled to have someone of marions caliber and experience join our team and i look forward to her contributions as we expand our efforts to improve the lives of patients who need new treatment options christophs passion vision and insights have been critical to blueprint medicines success to date and i look forward to him bringing that same energy to his new role where he will continue to be a catalyst in the companys success continued mr albers  christoph is renowned throughout the industry as an expert in precision medicine and in his new position christoph will continue to inform our strategy as well as drive an integrated approach to moving our compounds from discovery through development at a critical time for blueprint as we progress our broad pipeline dr dorsch joins blueprint medicines from agios pharmaceuticals inc agios where she served as vice president of biology in this role she was responsible for novel target validation drug discovery and biomarker strategy across agios cancer rare genetic diseases and immunooncology portfolios during her tenure at agios dr dorsch contributed to the successful advancement of several molecules targeting defined genetic lesions into clinical trials prior to joining agios dr dorsch was the director of cancer biology at sanofi oncology where she oversaw drug discovery efforts earlier in her career dr dorsch served as research project leader for sonidegib odomzo now approved in the us and eu for the treatment of locally advanced basal cell carcinoma at the novartis institutes for biomedical research and also worked in inflammation discovery at millennium pharmaceuticals dr dorsch received her phd in biology from the free university of berlin germany and was a postdoctoral fellow at columbia university in new york i am thrilled to join blueprint medicines at this exciting time said dr dorsch the companys novel drug discovery approach has demonstrated a unique ability to target both validated genomic drivers of disease that have historically proven tough to address scientifically as well as programs directed towards novel targets resulting from blueprints genomic insights i believe blueprint medicines has multiple potential opportunities to expand its pipeline and i look forward to working with the companys scientists to further leverage blueprints proprietary compound library to evaluate the role of unexplored kinases in driving disease marion and i worked together closely at both novartis and sanofi and i cannot imagine anyone better suited to take on the role of chief scientific officer at blueprint medicines marion is a talented scientist and an excellent leader making her the perfect fit to direct and continue to build the science organization i am personally very excited to have the opportunity to work with marion again and believe our complementary contributions will best position blueprint in its mission to bring transformative medicines to patients said dr lengauer  i am also thrilled to be staying intimately involved with blueprint in a role that has the unique strategic imperative to integrate cross functional efforts across the exceptional talents throughout blueprint and to balance our focus between the broad strategic view and daytoday execution on our exciting pipeline of investigational drugs about blueprint medicines blueprint medicines is developing a new generation of targeted kinase medicines to improve the lives of patients with genomically defined diseases the companys approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases blueprint medicines is advancing three programs in clinical development for subsets of patients with gastrointestinal stromal tumors hepatocellular carcinoma and systemic mastocytosis as well as multiple programs in research and preclinical development for more information please visit wwwblueprintmedicinescom cautionary note regarding forwardlooking statements this press release contains forwardlooking statements within the meaning of the private securities litigation reform act of  as amended including without limitation statements regarding blueprint medicines strategy business plans and focus the words may will could would should expect plan anticipate intend believe estimate predict project potential continue target and similar expressions are intended to identify forwardlooking statements although not all forwardlooking statements contain these identifying words any forwardlooking statements in this press release are based on managements current expectations and beliefs and are subject to a number of risks uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forwardlooking statements contained in this press release including without limitation risks and uncertainties related to the delay of any current or planned clinical trials or the development of blueprint medicines drug product candidates including blu and blu blueprint medicines advancement of multiple earlystage efforts blueprint medicines ability to successfully demonstrate the efficacy and safety of its drug product candidates the preclinical and clinical results for blueprint medicines drug product candidates which may not support further development of such drug product candidates and actions of regulatory agencies which may affect the initiation timing and progress of clinical trials blueprint medicines ability to develop and commercialize companion diagnostics for its current and future drug candidates including companion diagnostics for blu with ventana medical systems inc and for blu with qiagen manchester limited and the success of blueprint medicines rare genetic disease collaboration with alexion pharma holding and its cancer immunotherapy collaboration with f hoffmannla roche ltd and hoffmannla roche inc these and other risks and uncertainties are described in greater detail in the section entitled risk factors in blueprint medicines quarterly report on form q for the quarter ended september   as filed with the securities and exchange commission sec on november   and other filings that blueprint medicines may make with the sec in the future any forwardlooking statements contained in this press release represent blueprint medicines views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date blueprint medicines explicitly disclaims any obligation to update any forwardlooking statements logo  httpphotosprnewswirecomprnhlogo to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasesblueprintmedicinesannouncesappointmentofmariondorschphdaschiefscientificofficerandthetransitionofchristophlengauerphdmbatoanewlycreatedexecutivevicepresidentrolehtml source blueprint medicines corporation the information on this page is provided by pr newswire all rights reserved reproduction or redistribution of this content without prior written consent from pr newswire is strictly prohibited is not responsible for this content learn more about this service about pr newswire the information on this page is provided by pr newswire the business journals is not responsible for this content learn more dorsch marion  blueprint medicines insider transactions  tipranks go prologin  sign up follow✓get real time transactionsinsider detailsdorsch marionblueprint medicines bpmcchief scientific officer not rankeddorsch marions performancedorsch marion has not reported any informative transactions and therefore cannot be rankedhow are insiders ranked dorsch marions trading historybased on form  follow✓get real time transactionscompany nameinsider positionholding valuelast transactionlast transaction amountlast transaction datebpmcblueprint medicineschief scientific officerdorsch marion has not reported any informative transactions for bpmc therefore performance cannot be measuredsee all insider trading from today you may also likemeet our smart portfolio see what top analysts say about your stocksget a breakdown of the different strategies based on detected insider trading activityfind the best performing analyst in each sector follow them so you never miss a recommendationrelated linkshow can i benefit from insider trading see the top  corporate insiders go to hot stocks by insiders find which stocks insiders traded today become a tipranks memberget the best investing tips  hacks straight to your emailfree membershipsubmitinsider trading daily newsletterprofessional daytrading strategy based on predictive insider transactionsannual return learn more powered by blueprint medicines announces appointment of marion dorsch phd as chief scientific officer and blueprint medicines announces appointment of marion dorsch phd as chief scientific officer and the transition of christoph lengauer phd mba to a newly created executive vice president role  effective november    news provided by blueprint medicines corporation nov    et share this article cambridge mass nov   prnewswire  blueprint medicines corporation nasdaq bpmc a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases today announced that marion dorsch phd will succeed christoph lengauer phd mba as chief scientific officer effective november   dr dorsch will join the executive management team and will be responsible for setting the scientific strategy and priorities for blueprint medicines as well as overseeing daytoday research operations dr lengauer will transition to the role of executive vice president where he will drive an integrated approach to progressing blueprint medicines portfolio of investigational drugs i am delighted to welcome marion to blueprint she is a seasoned leader with a deep understanding of human biology and a wealth of experience identifying novel drug targets for cancer and rare genetic diseases including significant experience in cancer immunology said jeff albers chief executive officer of blueprint medicines her expertise driving drug discovery across both internal and partnered programs will be invaluable as we continue to explore the vast potential of kinase therapies i am thrilled to have someone of marions caliber and experience join our team and i look forward to her contributions as we expand our efforts to improve the lives of patients who need new treatment options christophs passion vision and insights have been critical to blueprint medicines success to date and i look forward to him bringing that same energy to his new role where he will continue to be a catalyst in the companys success continued mr albers  christoph is renowned throughout the industry as an expert in precision medicine and in his new position christoph will continue to inform our strategy as well as drive an integrated approach to moving our compounds from discovery through development at a critical time for blueprint as we progress our broad pipeline dr dorsch joins blueprint medicines from agios pharmaceuticals inc agios where she served as vice president of biology in this role she was responsible for novel target validation drug discovery and biomarker strategy across agios cancer rare genetic diseases and immunooncology portfolios during her tenure at agios dr dorsch contributed to the successful advancement of several molecules targeting defined genetic lesions into clinical trials prior to joining agios dr dorsch was the director of cancer biology at sanofi oncology where she oversaw drug discovery efforts earlier in her career dr dorsch served as research project leader for sonidegib odomzo now approved in the us and eu for the treatment of locally advanced basal cell carcinoma at the novartis institutes for biomedical research and also worked in inflammation discovery at millennium pharmaceuticals dr dorsch received her phd in biology from the free university of berlin germany and was a postdoctoral fellow at columbia university in new york i am thrilled to join blueprint medicines at this exciting time said dr dorsch the companys novel drug discovery approach has demonstrated a unique ability to target both validated genomic drivers of disease that have historically proven tough to address scientifically as well as programs directed towards novel targets resulting from blueprints genomic insights i believe blueprint medicines has multiple potential opportunities to expand its pipeline and i look forward to working with the companys scientists to further leverage blueprints proprietary compound library to evaluate the role of unexplored kinases in driving disease marion and i worked together closely at both novartis and sanofi and i cannot imagine anyone better suited to take on the role of chief scientific officer at blueprint medicines marion is a talented scientist and an excellent leader making her the perfect fit to direct and continue to build the science organization i am personally very excited to have the opportunity to work with marion again and believe our complementary contributions will best position blueprint in its mission to bring transformative medicines to patients said dr lengauer  i am also thrilled to be staying intimately involved with blueprint in a role that has the unique strategic imperative to integrate cross functional efforts across the exceptional talents throughout blueprint and to balance our focus between the broad strategic view and daytoday execution on our exciting pipeline of investigational drugs about blueprint medicines blueprint medicines is developing a new generation of targeted kinase medicines to improve the lives of patients with genomically defined diseases the companys approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases blueprint medicines is advancing three programs in clinical development for subsets of patients with gastrointestinal stromal tumors hepatocellular carcinoma and systemic mastocytosis as well as multiple programs in research and preclinical development for more information please visit wwwblueprintmedicinescom cautionary note regarding forwardlooking statements this press release contains forwardlooking statements within the meaning of the private securities litigation reform act of  as amended including without limitation statements regarding blueprint medicines strategy business plans and focus the words may will could would should expect plan anticipate intend believe estimate predict project potential continue target and similar expressions are intended to identify forwardlooking statements although not all forwardlooking statements contain these identifying words any forwardlooking statements in this press release are based on managements current expectations and beliefs and are subject to a number of risks uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forwardlooking statements contained in this press release including without limitation risks and uncertainties related to the delay of any current or planned clinical trials or the development of blueprint medicines drug product candidates including blu and blu blueprint medicines advancement of multiple earlystage efforts blueprint medicines ability to successfully demonstrate the efficacy and safety of its drug product candidates the preclinical and clinical results for blueprint medicines drug product candidates which may not support further development of such drug product candidates and actions of regulatory agencies which may affect the initiation timing and progress of clinical trials blueprint medicines ability to develop and commercialize companion diagnostics for its current and future drug candidates including companion diagnostics for blu with ventana medical systems inc and for blu with qiagen manchester limited and the success of blueprint medicines rare genetic disease collaboration with alexion pharma holding and its cancer immunotherapy collaboration with f hoffmannla roche ltd and hoffmannla roche inc these and other risks and uncertainties are described in greater detail in the section entitled risk factors in blueprint medicines quarterly report on form q for the quarter ended september   as filed with the securities and exchange commission sec on november   and other filings that blueprint medicines may make with the sec in the future any forwardlooking statements contained in this press release represent blueprint medicines views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date blueprint medicines explicitly disclaims any obligation to update any forwardlooking statements logo  httpphotosprnewswirecomprnhlogo to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasesblueprintmedicinesannouncesappointmentofmariondorschphdaschiefscientificofficerandthetransitionofchristophlengauerphdmbatoanewlycreatedexecutivevicepresidentrolehtml source blueprint medicines corporation related links httpwwwblueprintmedicinescom nov    et preview blueprint medicines announces proofofconcept data from global phase  clinical trial of blu in patients with advanced hepatocellular carcinoma nov    et preview blueprint medicines to present preliminary data from ongoing phase  clinical trial for blu in advanced systemic mastocytosis at  ash annual meeting my news release contains wide tables view fullscreen also from this source jul 7   et blueprint medicines to evaluate opportunities to advance rare jul    et blueprint medicines to report second quarter  financial explore more news releases in similar topics biotechnology health care  hospitals medical pharmaceuticals pharmaceuticals personnel announcements you just read blueprint medicines announces appointment of marion dorsch phd as chief scientific officer and the transition of christoph lengauer phd mba to a newly created executive vice president role news provided by blueprint medicines corporation nov    et share this article looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search blueprint medicines announces appointment of marion dorsch phd as chief scientific officer and the transition of christoph lengauer phd mba to a newly created executive vice president rolehomemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoretry yahoo finance on firefox »yahoosearchsearchsign inus markets close in  hrs 7 minssp 7 7dow  nasdaq77 blueprint medicines announces appointment of marion dorsch phd as chief scientific officer and the transition of christoph lengauer phd mba to a newly created executive vice president rolepr newswirenovember  reblogsharetweetsharecambridge mass nov   prnewswire  blueprint medicines corporation bpmc a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases today announced that marion dorsch phd will succeed christoph lengauer phd mba as chief scientific officer effective november   dr dorsch will join the executive management team and will be responsible for setting the scientific strategy and priorities for blueprint medicines as well as overseeing daytoday research operations dr lengauer will transition to the role of executive vice president where he will drive an integrated approach to progressing blueprint medicines portfolio of investigational drugsblueprint medicinesmorei am delighted to welcome marion to blueprint she is a seasoned leader with a deep understanding of human biology and a wealth of experience identifying novel drug targets for cancer and rare genetic diseases including significant experience in cancer immunology said jeff albers chief executive officer of blueprint medicines her expertise driving drug discovery across both internal and partnered programs will be invaluable as we continue to explore the vast potential of kinase therapies i am thrilled to have someone of marions caliber and experience join our team and i look forward to her contributions as we expand our efforts to improve the lives of patients who need new treatment optionschristophs passion vision and insights have been critical to blueprint medicines success to date and i look forward to him bringing that same energy to his new role where he will continue to be a catalyst in the companys success continued mr albers  christoph is renowned throughout the industry as an expert in precision medicine and in his new position christoph will continue to inform our strategy as well as drive an integrated approach to moving our compounds from discovery through development at a critical time for blueprint as we progress our broad pipelinedr dorsch joins blueprint medicines from agios pharmaceuticals inc agios where she served as vice president of biology in this role she was responsible for novel target validation drug discovery and biomarker strategy across agios cancer rare genetic diseases and immunooncology portfolios during her tenure at agios dr dorsch contributed to the successful advancement of several molecules targeting defined genetic lesions into clinical trials prior to joining agios dr dorsch was the director of cancer biology at sanofi oncology where she oversaw drug discovery efforts earlier in her career dr dorsch served as research project leader for sonidegib odomzo now approved in the us and eu for the treatment of locally advanced basal cell carcinoma at the novartis institutes for biomedical research and also worked in inflammation discovery at millennium pharmaceuticals dr dorsch received her phd in biology from the free university of berlin germany and was a postdoctoral fellow at columbia university in new yorki am thrilled to join blueprint medicines at this exciting time said dr dorsch the companys novel drug discovery approach has demonstrated a unique ability to target both validated genomic drivers of disease that have historically proven tough to address scientifically as well as programs directed towards novel targets resulting from blueprints genomic insights i believe blueprint medicines has multiple potential opportunities to expand its pipeline and i look forward to working with the companys scientists to further leverage blueprints proprietary compound library to evaluate the role of unexplored kinases in driving diseaseread moremarion and i worked together closely at both novartis and sanofi and i cannot imagine anyone better suited to take on the role of chief scientific officer at blueprint medicines marion is a talented scientist and an excellent leader making her the perfect fit to direct and continue to build the science organization i am personally very excited to have the opportunity to work with marion again and believe our complementary contributions will best position blueprint in its mission to bring transformative medicines to patients said dr lengauer  i am also thrilled to be staying intimately involved with blueprint in a role that has the unique strategic imperative to integrate cross functional efforts across the exceptional talents throughout blueprint and to balance our focus between the broad strategic view and daytoday execution on our exciting pipeline of investigational drugsabout blueprint medicinesblueprint medicines is developing a new generation of targeted kinase medicines to improve the lives of patients with genomically defined diseases the companys approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases blueprint medicines is advancing three programs in clinical development for subsets of patients with gastrointestinal stromal tumors hepatocellular carcinoma and systemic mastocytosis as well as multiple programs in research and preclinical development for more information please visit wwwblueprintmedicinescomcautionary note regarding forwardlooking statementsthis press release contains forwardlooking statements within the meaning of the private securities litigation reform act of  as amended including without limitation statements regarding blueprint medicines strategy business plans and focus the words may will could would should expect plan anticipate intend believe estimate predict project potential continue target and similar expressions are intended to identify forwardlooking statements although not all forwardlooking statements contain these identifying words any forwardlooking statements in this press release are based on managements current expectations and beliefs and are subject to a number of risks uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forwardlooking statements contained in this press release including without limitation risks and uncertainties related to the delay of any current or planned clinical trials or the development of blueprint medicines drug product candidates including blu and blu blueprint medicines advancement of multiple earlystage efforts blueprint medicines ability to successfully demonstrate the efficacy and safety of its drug product candidates the preclinical and clinical results for blueprint medicines drug product candidates which may not support further development of such drug product candidates and actions of regulatory agencies which may affect the initiation timing and progress of clinical trials blueprint medicines ability to develop and commercialize companion diagnostics for its current and future drug candidates including companion diagnostics for blu with ventana medical systems inc and for blu with qiagen manchester limited and the success of blueprint medicines rare genetic disease collaboration with alexion pharma holding and its cancer immunotherapy collaboration with f hoffmannla roche ltd and hoffmannla roche inc these and other risks and uncertainties are described in greater detail in the section entitled risk factors in blueprint medicines quarterly report on form q for the quarter ended september   as filed with the securities and exchange commission sec on november   and other filings that blueprint medicines may make with the sec in the future any forwardlooking statements contained in this press release represent blueprint medicines views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date blueprint medicines explicitly disclaims any obligation to update any forwardlooking statementslogo  httpphotosprnewswirecomprnhlogoto view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasesblueprintmedicinesannouncesappointmentofmariondorschphdaschiefscientificofficerandthetransitionofchristophlengauerphdmbatoanewlycreatedexecutivevicepresidentrolehtmlreblogsharetweetsharerecently viewedyour list is emptywhat to read nextthe next aids pandemicforeign policy magazineengineer finds pattern makes millions in stocksmoney morningsponsoredis a beat in the cards for pfizer pfe in q earningszackstrump’s unwitting legacy could be universal health coverageyahoo financeus economic growth picks up in second quarter wages continue to lagreuterszuckerberg wifes ambitious secret finally exposedunewzmesponsoredsean hannity responds to claim he ran up a  tab at trumps hotel after flying in a yearold lobster from mainebusiness insidertwitter is only famous now because of president trump nyse traderyahoo finance videogdp — what you need to know in markets on fridayyahoo financea pennycrypto miracle making some americans richagora financialsponsoredis a surprise coming for apple aapl this earnings seasonzacksexxons profit doubles but still misses expectationsassociated pressamazon misses wall street expectations by a milebusiness insiderdiscover it  out of  avg by k customersdiscover cardsponsoredamazon could be the first trillion dollar company nyse traderyahoo finance videorollsroyce motor ceo we’re not in the auto business we’re in the luxury businessyahoo finance‘what happened’ hillary’s new book isn’t out yet but twitter is already making fun of the titleenufznuf what happened i will tell you what happened she was a terrible candidate a liar a hater of america a socialist progressive who wanted to destroy america from within and our great constitution america truly dodged a bullet when she didnt get elected to the presidency of the united statesshe was responsible for the deaths of  brave americans in libya she did nothing but set by and watch them be brutally murdered she leaked classified information to our enemies she knowingly used a private server doing all she could to destroy america from withinher along with her husband bill clinton are pure evil i can go on but i thank you understand and get my pointjoin the conversation  k